Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
Logo Image
|Articles|August 11, 2021

PET/MRI + Radiopharmaceuticals Can Identify Malignant Brain Tumors

Combination can also help patients avoid unnecessary invasive procedures.

Pairing PET/MRI imaging with radiopharmaceuticals can offer double benefits to patients. Not only can it accurately pinpoint malignant brain tumors, but it can help individuals side-step invasive procedures.

Although this combination, including radiopharmaceuticals, such as 18F-fluorethyl tyrosine (18F-FET), is already known to improve diagnostic performance, less is known about the role it plays in clinical decision-making.

In a study published recently in the Journal of Nuclear Medicine, a team of investigators from Germany examined how the combination worked with patients who have brain tumors.

For their study, the team led by Cornelia Brendle from the University Hospital Tuebingen radiology department, evaluated how well 18F-FET PET/MR performed in detecting malignant brain tumors. Not only did the combination pinpoint these tumors with 85-percent accuracy, it also changed patient management decisions in 33 percent of cases. Additionally, the findings from the combination helped 20 percent of patients avert unnecessary follow-up procedures.

Based on these outcomes, the team said, it is possible that the combination could help patients who have non-malignant brain tumors who could likely fare better with a watchful waiting approach.

To reach their results, the team conducted a retrospective investigation with 189 patients who had brain tumors and who underwent multi-parametric 18F-FET PET/MR imaging between 2017 and 2018. Patients were considered to have a new diagnosis if the scan detected any untreated, suspicious lesions.

According to their analysis, in 93 percent of cases, this combination approach was able to successfully detect both actively growing malignant tumors or those that were being successfully treated. Consequently, this type of imaging option could help inform clinical decisions that could bring the most appropriate treatment options to patients in the most timely way.

Although further research is needed, the team said, the combination approach can offer benefits to patients.

“Adding 18F-FET PET to MRI…in a hybrid scanner has been reported to be reasonable in terms of cost-effectiveness in selected patients,” they said.

For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.

Related to this article

View more
Emerging Research Insights and New Advances in Neuroradiology
Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Read more
Radiology and Building the Alzheimer’s Care Pathway of the Future
Radiology and Building the Alzheimer’s Care Pathway of the Future
Given the increasing prevalence of Alzheimer’s disease and a staggering number of people with dementia who are undiagnosed, this author discusses five essential keys for radiologists and their colleagues to facilitate earlier detection, precision care treatment and monitoring to help ensure timely care and intervention.
Read more